MRNA Moderna Inc
Price (delayed)
$72.89
Market cap
$28.02B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$15.37
Enterprise value
$26.78B
Moderna is an American, Cambridge, Massachusetts-based biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA . The Moderna technology platform is to insert
Highlights
The quick ratio has grown by 32% YoY
MRNA's gross profit has plunged by 73% YoY but it is up by 44% from the previous quarter
The gross margin has grown by 47% from the previous quarter but it has contracted by 43% YoY
MRNA's revenue has dropped by 53% year-on-year
The debt has grown by 31% year-on-year and by 2.6% since the previous quarter
Key stats
What are the main financial stats of MRNA
Market
Valuations
Earnings
Shares outstanding
384.4M
Market cap
$28.02B
Enterprise value
$26.78B
Price to book (P/B)
2.39
Price to sales (P/S)
5.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.3
Revenue
$5.05B
EBIT
-$4.33B
EBITDA
-$3.8B
Free cash flow
-$3.98B
Per share
Balance sheet
Liquidity
EPS
-$15.37
Free cash flow per share
-$10.36
Book value per share
$30.56
Revenue per share
$13.15
TBVPS
$40.83
Total assets
$15.68B
Total liabilities
$3.97B
Debt
$1.24B
Equity
$11.71B
Working capital
$7.3B
Debt to equity
0.11
Current ratio
4.09
Quick ratio
3.66
Net debt/EBITDA
0.32
Margins
Efficiency
Dividend
EBITDA margin
-75.3%
Gross margin
33%
Net margin
-116.2%
Operating margin
-91.8%
Return on assets
-33.4%
Return on equity
-45.3%
Return on invested capital
-32.9%
Return on capital employed
-32.5%
Return on sales
-85.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRNA stock price
How has the Moderna stock price performed over time
Intraday
-0.75%
1 week
-5.83%
1 month
-11.43%
1 year
-32.66%
YTD
-26.71%
QTD
-38.62%
Financial performance
How have Moderna's revenue and profit performed over time
Revenue
$5.05B
Gross profit
$1.67B
Operating income
-$4.64B
Net income
-$5.87B
Gross margin
33%
Net margin
-116.2%
MRNA's gross profit has plunged by 73% YoY but it is up by 44% from the previous quarter
MRNA's revenue has dropped by 53% year-on-year
The gross margin has grown by 47% from the previous quarter but it has contracted by 43% YoY
The operating income has grown by 10% from the previous quarter
Growth
What is Moderna's growth rate over time
Valuation
What is Moderna stock price valuation
P/E
N/A
P/B
2.39
P/S
5.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.3
MRNA's P/B is 64% below its 5-year quarterly average of 6.7 and 25% below its last 4 quarters average of 3.2
The equity is down by 31% YoY and by 9% QoQ
The stock's P/S is 87% below its 5-year quarterly average of 43.4 and 17% below its last 4 quarters average of 6.7
MRNA's revenue has dropped by 53% year-on-year
Efficiency
How efficient is Moderna business performance
MRNA's return on equity is down by 8% since the previous quarter
The company's return on sales rose by 8% QoQ
Moderna's ROA has decreased by 7% from the previous quarter
The ROIC has grown by 3.2% from the previous quarter
Dividends
What is MRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRNA.
Financial health
How did Moderna financials performed over time
The quick ratio has grown by 32% YoY
Moderna's total assets has decreased by 28% YoY and by 6% from the previous quarter
The debt is 89% smaller than the equity
The company's debt to equity has surged by 83% YoY and by 22% QoQ
The debt has grown by 31% year-on-year and by 2.6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.